Kardigan, Inc. Common Stock (KARD)

PHARMACEUTICAL PREPARATIONS

Kardigan, Inc. Common Stock (KARD) is listed on Nasdaq, where it has traded since June 18, 2026.

Listed On
Nasdaq
Listed Since
June 18, 2026
Market Cap
$1.4B

About Kardigan, Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 65 institutions reported holding KARD, with 57.2 million shares worth $1.4 billion in aggregate. The largest reported holder was Schf (Gpe), with 16.9 million shares worth $403.5 million. Of the 5 largest holders listed below, all 5 opened new positions in KARD during the quarter.

InstitutionSharesValueQuarter change
Schf (Gpe)16,917,034$403MNew position
FMR8,909,066$212MNew position
Perceptive Advisors8,200,662$196MNew position
T. Rowe Price4,865,917$116MNew position
Capital Group3,598,942$86MNew position

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is KARD?

Kardigan, Inc. Common Stock (KARD) is listed on Nasdaq, where it has traded since June 18, 2026.

Who are the largest institutional holders of KARD?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of KARD were Schf (Gpe), FMR and Perceptive Advisors.

How many institutions own KARD?

65 institutions reported a position in KARD for the quarter ended June 30, 2026, worth $1.4 billion in total.

Did institutions buy or sell KARD last quarter?

Of the 5 largest reported holders, all 5 opened new positions in KARD during the quarter. Every reported holder and its change is on the SentiSense ownership page for KARD.

Every reported institutional holder, plus insider and congressional trades in KARD, on SentiSense.